Weight Loss Drugs Impact Beauty and Retail Sales
Left 33%
Center 67%
Right 0%
1 left · 2 center · 0 right
What happened
L'Oreal chief executive Nicolas Hieronimus told an investor call that rising use of GLP-1 weight-loss drugs is affecting beauty and skincare consumption. The company reported that sales for the three months to September rose 7.7 percent, above analyst expectations. L'Oreal said its SkinCeuticals and Kiehl's brands have products designed to address side effects of rapid weight loss, including skin sagging, and it raised its stake in dermatology firm Galderma to 20 percent last December. Reuters reported that L'Oreal and Galderma have been testing products on GLP-1 users concerned about loose skin. GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, first developed for diabetes, have become widely used for weight loss because they suppress appetite.
Sourcing check · Fully on the record · 3 articles
2 of 2 articles cite a named source for the story. It was on the record from the first report.
What these terms mean and how they're counted
- On the record · names a source 2 of 2
- On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Nicolas Hieronimus, L'Oreal and EY-Parthenon
- Primary evidence · cites a document or data 0 of 2
- Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: None cited.
- Credits another outlet 0 of 2
- The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
- Unnamed sources 0 of 2
- The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
- How it developed
- When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 22, 22:27 UTC by BBC, naming its source.
- Not counted 1
- Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
BLINDSPOT.
Only left-leaning outlets are covering this story
— the other side's media is silent.
Omitted — what each side leaves out
Unpacked
Right-leaning coverage has not reported L'Oreal's claim that weight-loss drugs are affecting beauty and skincare sales. Left-leaning coverage says the company's head called the rise of those drugs "a very important phenomenon for us" and tied it to skin-care consumption. A reader who sees only the silent side would miss that L'Oreal is already designing SkinCeuticals and Kiehl's products for sagging skin, and that it has increased its stake in Galderma, whose injectables target facial volume.
Left-leaning coverage leads with that demand shift rather than with the company's results. Sales still rose by 7.7 percent in the same BBC account that treats GLP-1 use as a force on skin-care consumption.
How large a share of beauty spending does L'Oreal attribute to people using GLP-1 drugs?
Bottom line
The BBC carried L'Oreal's GLP-1 skincare warning alongside a 7.7 percent sales rise; right-leaning outlets carried neither.
The receipts — 4 facts one side's coverage lacks
- L'Oreal head Nicolas Hieronimus said the rise of GLP-1s is having an impact on beauty consumption and skin care consumption in particular
- L'Oreal increased its stake in dermatology firm Galderma to 20 percent last December
- Both L'Oreal and Galderma have been testing products on GLP-1 users worried about loose skin in separate clinical trials
- A Galderma survey of weight-loss medication users found the vast majority had noticed changes to their facial appearance
The Left View
BBC reported L'Oreal describing GLP-1 drugs as a very important phenomenon that is having an impact on beauty consumption and skincare consumption in particular, while also saying the beauty market has been resilient and that quarterly sales beat forecasts. The coverage focuses on L'Oreal's commercial response: products meant to complement GLP-1-related skin sagging, plus a larger move into clinical aesthetics through Galderma, which owns injectables including Sculptra and Restylane. BBC also noted Galderma's earlier survey of weight-loss medication users, which found that the vast majority had noticed changes in facial appearance, and that both companies have run related clinical tests.
Our Take (balanced)
The story is substantive: it rests on a named public-company executive speaking on an investor call, a specific quarterly sales figure, named brands and products, and a disclosed Galderma stake, with Reuters cited for clinical testing. What is established is L'Oreal's own account that GLP-1 use is affecting beauty and skincare consumption and that the firm is positioning products and an aesthetics investment around rapid-weight-loss skin effects. What is not established is the size of any sales impact, which coverage does not quantify, and the facial-change findings come from a company-linked user survey rather than independent medical records. No right-leaning outlet has reported this. Watch next for the investor-call transcript and any numeric breakout of GLP-1 effects on sales, published results from the L'Oreal and Galderma tests, and whether other major beauty companies make similar disclosures.
3 sources
More stories
The week's bottom lines, in your inbox
One email a week: the five stories that mattered and what they actually mean. Free.